Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin).

Bastie, J N; Suzan, F; Garcia, I; Isnard, F; de Revel, T; Terre, C; Mayeur, D; Abraham, C; Lavielle, R; Castaigne, S

Bastie, J N; Suzan, F; Garcia, I; Isnard, F; de Revel, T; Terre, C; Mayeur, D; Abraham, C; Lavielle, R; Castaigne, S.

Br J Haematol ; 116(4): 924, 2002 Mar.

Article in En | MEDLINE | ID: mdl-11886404

Subject(s)

Aminoglycosides; Anti-Bacterial Agents/adverse effects; Anti-Bacterial Agents/therapeutic use; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/therapeutic use; Hepatic Veno-Occlusive Disease/etiology; Leukemia, Myeloid/therapy; Adult; Aged; Antibodies, Monoclonal, Humanized; Female; Gemtuzumab; Humans; Male; Middle Aged

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Hepatic Veno-Occlusive Disease / Leukemia, Myeloid / Aminoglycosides / Anti-Bacterial Agents / Antibodies, Monoclonal Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 2002 Document type: Article

Search on Google

XML

PubMed Links